Trials / Unknown
UnknownNCT03715309
R2 in the Treatment of Follicular Lymphoma
R2 in the Treatment of Follicular Lymphoma Grade 1-3A
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 115 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 16 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Lenalidomide Based Immunotherapy in the Treatment of FL
Detailed description
Lenalidomide Based Immunotherapy efficacy related molecular biomarker in follicular lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Revlimid | Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0 |
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2020-11-01
- Completion
- 2020-11-01
- First posted
- 2018-10-23
- Last updated
- 2019-07-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03715309. Inclusion in this directory is not an endorsement.